GeoVax Labs, Inc. (GOVX-NASDAQ)

GeoVax Labs, Inc. (“GeoVax” or “the Company”) is a clinical-stage biotechnology company developing novel therapies and vaccines, respectively, for cancers and many of the world’s most threatening infectious diseases. The Company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate, GEO-CM04S1, is a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. GEO-CM04S1 is being evaluated in three Phase 2 clinical trials: (1) as a primary COVID-19 vaccine for immunocompromised patients versus mRNA vaccines; (2) as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines; and (3) as a more robust, durable booster versus mRNA vaccines in immunocompromised patients with chronic lymphocytic leukemia (CLL). GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades.

* The Corporate Snapshot was last updated on June 24, 2024.